
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of June 2026

Commission file number: 001-37891

AC IMMUNE SA

(Exact Name of Registrant as Specified in Its Charter)

EPFL Innovation Park

Building B

1015 Lausanne, Switzerland

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or
Form 40-F.

Form 20-F Form 40-F

On June 11, 2026, AC Immune SA (“AC Immune”) held its Annual General Meeting of Shareholders. The Management presentation to shareholders is attached hereto as Exhibit 99.1. The final results of all agenda items submitted to a vote of the shareholders are as below and the detailed results will be provided in the minutes which will be published on AC Immune’s website (<https://ir.acimmune.com/governance>) within 15 days:

Annual General Meeting Results

Agenda Item 1: 2025 IFRS Consolidated Financial Statements, 2025 Statutory Financial Statements, 2025 Compensation Report

Agenda Item 1.1: Approval of 2025 IFRS Consolidated Financial Statements and 2025 Statutory Financial Statements

AC Immune shareholders approved the 2025 IFRS Consolidated Financial Statements and the 2025 Statutory Financial Statements.

Agenda Item 1.2: Advisory Vote on the 2025 Compensation Report

AC Immune shareholders endorsed the 2025 Compensation Report.

Agenda Item 2: Appropriation of Losses

AC Immune shareholders approved that the net loss for the year 2025 in the amount of CHF 67,595K increases the “accumulated losses brought forward” of CHF 356,846K, resulting in a new balance of “accumulated losses brought forward” of CHF 424,441K.

Agenda Item 3: Discharge of the Members of the Board of Directors and the Executive Management

AC Immune shareholders approved the discharge of the Members of the Board of Directors and the Executive Management for the financial year 2025.

Agenda Item 4: Compensation for the Members of the Board of Directors and the Executive Management

Agenda Item 4.1: Binding Vote on Maximum Aggregate Compensation for Members of the Board of Directors from the AGM 2026 to the AGM 2027

AC Immune shareholders approved the total maximum amount of compensation for the Members of the Board of Directors of CHF 1,029K (excluding employer social security contributions) covering the period from the AGM 2026 to the AGM 2027.

Agenda Item 4.2: Binding Vote on Maximum Aggregate Compensation for Members of the Executive Management for the Financial Year 2027

AC Immune shareholders approved the total maximum amount of compensation for the Members of the Executive Management of CHF 6,742K (excluding employer social security contributions) from 1 January 2027 to 31 December 2027.

Agenda Item 5: Re-Elections

Agenda Item 5.1: Re-Elections of Members and the Chair of the Board of Directors

AC Immune shareholders approved the re-election of Renée Aguiar-Lucander, Monika Bütler, Carl June and Roy Twyman as Members of the Board of Directors and the re-election of Martin Zügel as Member and Chair of the Board of Directors, each until the end of the Annual General Meeting 2027.

Agenda Item 5.2: Re-Elections of Members of the Compensation, Nomination and Corporate Governance Committee

AC Immune shareholders approved the re-election of Monika Bütler and Roy Twyman as Members of the Compensation, Nomination and Corporate Governance Committee, each until the end of the Annual General Meeting 2027.

Agenda Item 5.3: Re-Election of the Statutory Auditors

AC Immune shareholders approved the re-election of PricewaterhouseCoopers SA, Lausanne, Switzerland, as AC Immune's Statutory Auditors for the financial year 2026.

Agenda Item 5.4: Re-Election of the Independent Proxy

AC Immune shareholders approved the re-election of Reymond & Associés Attorneys, Lausanne, as AC Immune's Independent Proxy until the end of the Annual General Meeting 2027.

Agenda Item 6: Changes in the Articles of Association

Agenda Item 6.1: Capital Band (Article 3a)

AC Immune shareholders approved the introduction of a capital band with an upper limit of CHF 2,862,500.00 and a lower limit of CHF 2,202,018.50, authorizing the Board to increase and/or decrease the Company's share capital one or several times within these limits until 11 June 2031, and accordingly to amend Article 3a of the Articles of Association as set out in the Invitation to the Annual General Meeting.

Agenda Item 6.2: Increase of Conditional Share Capital for Employee-Benefit Plans (Article 3c)

AC Immune shareholders approved the increase of the conditional share capital for employee benefit plans from CHF 86,683.80 to CHF 150,000.00 and the amendment of Article 3c of the Articles of Association as set out in the Invitation to the Annual General Meeting.

This Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (File Nos. 333-227016, 333-249655 and 333-277940) and Form S-8 (File Nos. 333-213865, 333-216539 and 333-233019) of AC Immune SA and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AC IMMUNE SA

By: /s/ Martin Zügel

Name: Martin Zügel
Title: Interim Chief Executive Officer

By: /s/ Christopher Roberts

Name: Christopher Roberts
Title: Chief Financial Officer

Date: June 11, 2026

EXHIBIT INDEX

Exhibit Number

Description

[99.1](#)

[Annual General Meeting Presentation](#)



PIONEERING PRECISION PREVENTION

TARGETED THERAPEUTICS
FOR NEURODEGENERATIVE DISEASES

Investor Update

NASDAQ: ACIU | Annual General Meeting – June 11, 2026



Disclaimer

This presentation contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, CH, EU, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CA, CH, CN, EU, GB, JP, KR, NO, RU and SG.

Agenda

-
1. AC Immune's approach to neurodegenerative diseases

 2. Achievements 2025

 3. Business update


 4. Key milestones 2026

 5. Financial figures

 6. Summary and Strategic outlook

 7. Agenda items and proposals of the Board of Directors
-

1. AC Immune's approach to neurodegenerative diseases



AC Immune – pioneering precision prevention of neurodegeneration

Next generation Precision Medicine for neurodegenerative diseases



Focused pipeline with active immunotherapies and intracellular targeted small molecule programs



Key differentiation: Precision Prevention enabled by leadership in targeting toxic proteins



Differentiated technology platforms validated through multiple clinical candidates and pharma partnering deals



Partnering: strategic, risk-mitigating, timely, monetization with >CHF 4.3 billion in potential milestones




Cash reserves on Balance sheet
Funding into Q4 2027

- Based in Lausanne, Switzerland
- ~120 employees
- Listed on NASDAQ: ACIU
- 102 million shares outstanding¹
- Cash resources of CHF 74.8 million²



(1) As of March 31, 2026; excluding treasury shares; (2) As of March 31, 2026 (~USD 94 million)

2. Achievements 2025



AC Immune 2025 highlights

Active immunotherapies

Targeted active immunotherapies:

- **ACI-7104**¹ (wholly-owned)
Phase 2 trial interims with **potential disease-modifying activity**
- **ACI-24**² (Takeda)
ABATE cohort completed 12-months treatment

Intracellular Targeting

Small molecule programs:

- Small molecule programs targeting Tau, a-syn³, and NLRP3⁴ reaching value inflection points
- NLRP3 inhibitor (wholly-owned) completed preclinical development (now in Phase 1)
- a-syn and TDP-43⁵ PET⁶ tracers in Phase 1 testing

Finance


Operating capital foundation:

- Significant restructuring in Q3 2025
 - ~30% headcount reduction
 - ~CHF 40 million savings
 - ~6 months cash runway extension
- Cash resources of CHF 91.4 million at year end provide runway into Q4 2027

Cash runway permits achievement of key milestones & execution of value-generating innovation

(1) Phase 2 Part 1; (2) Phase 1b/2; (3) Alpha-synuclein; (4) (NOD)-like receptor protein 3; (5) TAR DNA-binding protein 43; (6) Positron emission tomography

3. Business update



Our value drivers achieving Precision Prevention through Active Immunotherapy complemented by Intracellular Targeting

Active Immunotherapies

ACI-35.030 anti-pTau

The only active immunotherapy in a prevention study for pre-symptomatic Alzheimer's disease

ACTIVE Immune Therapy



ACI-24.060 anti-Abeta

Biomarker-driven development targeting the hallmark protein in Alzheimer's disease and Alzheimer's in Down syndrome

ACTIVE Immune Therapy



ACI-7104.056 anti-a-syn

Active immunotherapy targeting pathological a-syn in early-stage Parkinson's disease

ACTIVE Immune Therapy

Brain penetrant SM¹

Intracellular targeting

Small molecule programs targeting intracellular pathologies:

- Tau *Lilly*
- a-syn
- NLRP3 inflammasome

(1) Small molecules





NASDAQ: ACIU | AGM Presentation, June 11, 2026

© 2026 AC Immune. Not to be used or reproduced without permission

9

AC Immune

Pipeline focused on Precision Prevention for neurodegenerative diseases: Active Immunotherapies and Intracellular Targeting


Modality	Candidate	Partner	Indication	Discovery	Preclinical	Phase 1	Phase 2	Phase 3
Active Immunotherapy	ACI-35.030 (JNJ-2056)		Alzheimer's disease (<i>pTau</i> ¹)	FDA Fast Track				
	ACI-24.060		Alzheimer's disease (<i>Abeta</i> ²)	FDA Fast Track				
			Alzheimer's disease: Down Syndrome					
	ACI-7104.056		Parkinson's disease (<i>a-syn</i> ³)					
Intracellular Targeting	ACI-19764		Neuro-inflammation (<i>NLRP3</i> ⁴)					
	Morphomer Tau		Alzheimer's disease (<i>Tau</i>)					
	Morphomer® a-syn		Parkinson's disease (<i>a-syn</i>)					
Tracer	PI-2620		Alzheimer's disease, PSP ⁵ and others (<i>Tau</i>)	FDA Fast Track				

(1) Phosphorylated Tau; (2) amyloid beta; (3) alpha-synuclein; (4) (NOD)-like receptor protein 3; (5) Progressive supranuclear palsy

Active immunotherapy programs:

Targeting Abeta, Tau, and a-syn


ACTIVE 
Immune Therapy



Major advantages

- ✓ Long-lasting specific immunity for pathological target, consistent, boostable
- ✓ Limited annual dosing (once or twice) after priming year
- ✓ No observed ARIA-E¹ to date (safety profile well suited to long-term use)
- ✓ Ease of administration and simple logistics for global access
- ✓ Cost-effective (attractive healthcare economics across global populations)

(1) Amyloid-related imaging abnormalities-edema



Active immunotherapy

Stimulates the patient's immune system to produce their own antibodies

Passive immunotherapy

Externally generated mAb requires administration every two to four weeks



Active immunotherapies driving Precision Prevention

Three clinical-stage programs supported by promising data from prior trials

Candidate	Indication	Discovery	Preclinical	Phase 1	Phase 2	Status
ACI-24 (<i>anti-Abeta</i>)	AD ¹ treatment			FDA Fast Track		Phase 1b/2 ABATE trial ongoing
	AD treatment (<i>Down syndrome</i> ²)					
ACI-35 / JNJ-2056 (<i>anti-pTau</i>)	AD therapy			FDA Fast Track		Phase 2b ReTain trial ongoing
ACI-7104 (<i>anti-a-syn</i> ³)	PD ⁴ , a-synucleinopathies					Phase 2 VacSYn trial ongoing

ACI-35 anti-pTau




ACI-24 anti-Abeta





ACI-7104 anti-a-syn






(1) Alzheimer's disease; (2) Down syndrome-related Alzheimer's disease; (3) alpha-synuclein; (4) Parkinson's disease

Active immunotherapy: a new class of treatment for neurodegenerative disease


Potential for profound social and economic impact



 **ACTIVE**  **Immune Therapy** for global treatment and prevention of neurodegenerative diseases

Small molecule programs:

Targeting intracellular NLRP3, Tau, and a-syn



Intracellular Targeting for earliest pathology intervention in NDD¹

Brain penetrant small molecules as a key differentiator

- 1 Optimal delivery into the central nervous system
- 2 Cell-penetrant with proven engagement of their specific intracellular target
- 3 Conformation-specific and highly selective for misfolded forms of target proteins in NDD, i.e. Tau, a-syn² and TDP-43³
- 4 Potential application across all pathological and disease stages
- 5 Oral, cost-effective and convenient administration

■ Unique product and commercial opportunities over other modalities

(1) Neurodegenerative diseases; (2) Alpha-synuclein; (3) TAR DNA binding protein-43

Intracellular Targeting pipeline focused on neurodegenerative diseases

Programs now close supported by promising data from prior trials

Candidate	Indication	Discovery	Preclinical	Phase 1	Phase 2	Phase 3
ACI-19764	Neuro-inflammation (<i>NLRP3</i> ¹)	[Progress bar: Discovery, Preclinical, Phase 1]				
Morphomer [®] Tau	Alzheimer's disease (<i>Tau</i>)	[Progress bar: Discovery, Preclinical]				
Morphomer [®] a-syn ²	Parkinson's disease (<i>a-syn</i>)	[Progress bar: Discovery]				

ACI-19764
NLRP3 inhibitor



Morphomer[®]
Tau



Morphomer[®]
a-syn



(1) (NOD)-like receptor protein 3; (2) alpha-synuclein

4. Key milestones 2026



Key milestones 2026


Multiple catalysts across pipeline

- Readouts
- Other development events

Active immunotherapies		H1 2026	H2 2026	
ACI-24 (Takeda)	Abeta	✔		ABATE Phase 2 trial in AD ¹ : first patient dosed in AD4 cohort
		●		ABATE Phase 2 trial readouts after 12 months of treatment (AD3: Abeta PET)
ACI-7104	a-syn ³	○		Discussions with regulators regarding clinical development plan
			●	Phase 2 VacSYn trial in PD ² : end of Part 1 study clinical results
			○	IND ⁴ /CTA ⁵ filing for next clinical trial
Small molecule drugs				
NLRP3 inhibitor (ACI-19764)	NLRP3 ⁶	✔		Phase 1 clinical trial in healthy volunteers initiated
			●	Phase 1 clinical trial in healthy volunteers completed
Morphomer-Tau (Lilly)	Tau	○		Initiation of IND-enabling studies in partnership with Lilly
Morphomer a-syn	a-syn		○	Readiness to initiate IND-enabling studies

(1) Alzheimer's disease; (2) Parkinson's disease; (3) Alpha-synuclein; (4) Investigational new drug; (5) Clinical Trial Application; (6) (NOD)-like receptor protein;

5. Financial figures



2025 Financial Overview

Key financial data (IFRS)

For the year ended December 31,	2025	2024	Change
			(in CHF million) (except per share data)
Revenues	3.6	27.3	(23.7)
R&D expenses	(56.4)	(62.6)	6.2
G&A expenses	(16.1)	(17.3)	1.2
Other operating income	0.1	0.1	0.0
Restructuring expenses, net	(0.5)	—	(0.5)
Total Operating expenses	(72.9)	(79.8)	6.9
Finance result, net	(1.1)	1.5	(2.6)
IFRS loss for the period	(70.4)	(51.0)	(19.4)
IFRS EPS – basic and diluted	(0.70)	(0.51)	(0.19)

As of December 31,	2025	2024	Change
			(in CHF million)
Cash and cash equivalents	26.8	36.3	(9.5)
Short-term financial assets	64.6	129.2	(64.6)
Total liquidity¹	91.4	165.5	(74.1)
Total shareholder's equity	44.9	112.3	(67.4)

(1) Liquidity is defined as the cash and cash equivalents plus short-term financial assets. These short-term financial assets are cash held in fixed-term deposits ranging in maturity from 3–12 months

AC Immune strong Balance Sheet

Operations well-funded into Q4 2027



Cash of CHF 74.8 million¹



2026 annual cash burn guidance
CHF 55m – 65m



Strong Balance Sheet²
Cash runway into Q4 2027

Investment
strategy focused
on major value
drivers and near-
term catalysts

(1) As of March 31, 2026; (2) Assumes no other milestones or deals included


NASDAQ: ACIU | AGM Presentation, June 11, 2026

© 2026 AC Immune. Not to be used or reproduced without permission

22


 AC Immune

6. Summary and Strategic outlook



Creating the future of Precision Medicine in neurodegeneration

The foundation for early detection and treatment



Cash runway enables achievement of key milestones & execution of value-generating innovation


(1) Phase 1b/2; (2) Phase 2; (3) Phase 2; (4) (NOD)-like receptor protein 3; (5) Positron emission tomography; (6) Alpha-synuclein; (7) TAR DNA-binding protein 43

Pioneering Precision Prevention

Shifting the treatment paradigm for neurodegenerative disease towards precision medicine and disease prevention



7. Agenda items and proposals of the Board of Directors



Agenda item 1

2025 IFRS Consolidated Financial Statements, 2025 Statutory Financial Statements, 2025 Compensation Report

1.1 Approval of 2025 IFRS Consolidated Financial Statements and 2025 Statutory Financial Statements

- The Board proposes that the 2025 IFRS Consolidated Financial Statements and the 2025 Statutory Financial Statements be approved

Agenda item 1

2025 IFRS Consolidated Financial Statements, 2025 Statutory Financial Statements, 2025 Compensation Report

1.2 Advisory Vote on the 2025 Compensation Report

- The Board proposes that the 2025 Compensation Report be endorsed (non-binding advisory vote)

Agenda item 2

Appropriation of Losses

- The Board proposes the following appropriation of losses:

	In CHF K
Accumulated profit (loss) at Jan 1, 2025	(356,846)
Net profit (loss) for the year 2025	(67,595)
Accumulated losses brought forward	(424,441)

Under IFRS accounting standards, the consolidated net loss for the business year 2025 amounted to CHF 70,447K

Agenda item 3

Discharge of the Members of the Board of Directors and the Executive Management

- The Board proposes that all Members of the Board and of the Executive Management be discharged from their liabilities for their activities in the financial year 2025

Agenda item 4

Compensation for the Members of the Board of Directors and the Executive Management

4.1 Binding Vote on Maximum Aggregate Compensation for Members of the Board of Directors from the AGM 2026 to the AGM 2027

- The Board proposes the approval of the total maximum amount of compensation for the Members of the Board of CHF 1,029,000 (excluding employer social security contributions) covering the period from the AGM 2026 to the AGM 2027.

Agenda item 4

Compensation for the Members of the Board of Directors and the Executive Management

4.2 Binding Vote on Maximum Aggregate Compensation for Members of the Executive Management for the Financial Year 2027

- The Board proposes the approval of the total maximum amount of compensation for the Members of the Executive Management of CHF 6,742,000 (excluding employer social security) from 1 January 2027 to 31 December 2027.

Agenda item 5

Re-Elections

5.1 Re-Elections of Members and the Chair of the Board of Directors

- The Board proposes that each of the following persons be re-elected for a term of office until the end of the AGM 2027:
 - Martin Zügel as Member and Chair of the Board
and as Members of the Board:
 - Renée Aguiar-Lucander
 - Monika Bütler
 - Carl June
 - Roy Twyman

Agenda item 5

Re-Elections

5.2 Re-Elections of Members of the Compensation, Nomination and Corporate Governance Committee

- The Board proposes that:

- Monika Büttler
- Roy Twyman

be re-elected as Members of the Compensation, Nomination and Corporate Governance Committee for a term of office until the end of the AGM 2027

Agenda item 5

Re-Elections

5.3 Re-Election of the Statutory Auditors

- The Board proposes that PricewaterhouseCoopers SA, in Lausanne, Switzerland, be re-elected as Statutory Auditors for the financial year 2026.

Agenda item 5

Re-Elections

5.4 Re-Election of the Independent Proxy

- The Board proposes that Reymond & Associés Attorneys in Lausanne, Switzerland be re-elected as Independent Proxy for a term of office until the end of the AGM 2027.

Agenda item 6

Changes in the Articles of Association

6.1 Capital Band (Article 3a)

- The Board proposes to introduce a capital band with an upper limit of CHF 2,862,500.00 and a lower limit of CHF 2,202,018.50, authorizing the Board to increase and/or decrease the Company's share capital one or several times within these limits until 11 June 2031, and accordingly to amend art. 3a of the Articles of Association, as set forth in the AGM Invitation.

Agenda item 6

Changes in the Articles of Association


6.2 Increase of Conditional Share Capital for Employee-Benefit Plans (Art. 3c)

- The Board proposes to increase the conditional share capital for employee benefit plans from CHF 86,683.80 to CHF 150,000.00 and accordingly to amend art. 3c of the Articles of Association, as set forth in the AGM Invitation.

We thank you for your attendance
and your continued support.



Back-up



Agenda item 6.1

Proposed Article 3a

1. The Company has a capital band ranging from CHF 2,202,018.50 corresponding to 110,100,925 registered shares with a par value of CHF 0.02 each, to be fully paid up (lower limit) to CHF 2,862,500.00, corresponding to 143,125,000 registered shares with a par value of CHF 0.02, each to be fully paid up (upper limit). The Board of Directors is authorized to conduct one or several increases and/or reductions of the share capital within the capital band at any time until 11 June 2031. An increase of the share capital (i) by means of an offering underwritten by a financial institution, a syndicate or another third party or third parties, followed by an offer to the then-existing shareholders of the Company and (ii) in partial amounts, shall also be permissible.
 - a) if the issue price of the new registered shares is determined by reference to the market price (with a customary discount); or
 - b) if the new registered shares are used for the acquisition of an enterprise, part of an enterprise or participations, or for the financing or refinancing of any of such acquisition, for the conversion of loans or claims into shares, for the financing of new investment projects undertaken by the Company, the acquisition or financing of products, intellectual property or licenses, or the financing of strategic initiatives undertaken, or in the event of share placement for the financing or refinancing of such placement; or
 - c) if the new registered shares are issued for raising of equity capital (including private placements) in a fast and flexible manner where such raising of capital would be difficult or would only be possible at less favorable conditions without the exclusion or restriction of the statutory pre-emptive right of the existing shareholders; or
 - d) if the new registered shares are used either to extend the shareholder base, to increase the free float or for investment by strategic partners; or
 - e) for the participation of Members of the Board of Directors, Members of the Executive Management, employees, contractors, consultants or other persons performing services for the benefit of the Company or any of its group companies, whereby increases of the share capital are only admissible up to 5% of the share capital entered in the commercial register at the time of the respective resolution; or
 - f) for other important reasons in the sense of art. 652b para. 2 CO.
2. In case of a capital increase, the following applies:
 - i. The Board of Directors shall determine the amount of share capital to be issued, the date of the issuance, the issue price, the manner in which the new registered shares have to be paid up (including cash contributions, contributions in kind, set-off and conversion of freely usable reserves, including retained earnings, into share capital), the date from which the registered shares carry the right to dividends, the conditions for the exercise of the pre-emptive rights and the allotment of pre-emptive rights that have not been exercised. The Board of Directors is authorized to restrict or to prohibit trading in the pre-emptive rights to the new shares. The Board of Directors may allow the pre-emptive rights that have not been exercised to expire, or it may place with third parties such rights or registered shares, the pre-emptive rights of which have not been exercised, at market conditions or use them otherwise in the interest of the Company.
 - ii. The Board of Directors is authorized to withdraw or limit the pre-emptive rights of the shareholders wholly or in part and to allot them to individual shareholders or third parties:

Agenda item 6.1

Proposed Article 3a (cont'd)

3. The subscription to and acquisition of new registered shares and any subsequent transfers of their ownership shall be subject to the restrictions specified in Article 4 of the Articles of Association.
4. Capital reductions may be performed both by reducing the par value of the shares and by cancelling shares. In case of a reduction of the par value, the Board of Directors shall adapt all provisions of the Articles of Association relating to the par value of the shares as well as the number of shares with a new nominal value corresponding to the fixed upper and lower limits of the capital band as per art. 3a para. 1 accordingly.
5. In case of a capital reduction within the capital band, the Board of Directors shall, to the extent necessary, determine the number of canceled shares and the use of the amount of the reduction.
6. The acquisition and holding of shares repurchased for purposes of cancellation under the capital band are, to the extent permitted by law, not subject to the 10% limit for own shares within the meaning of art. 659 para. 2 CO.
7. The Board of Directors is authorized to carry out simultaneous reductions and re-increases of the share capital.

Agenda item 6.2

Proposed Article 3c

1. The share capital of the Company shall be increased by an amount not exceeding CHF 150,000.00 through the issue of a maximum of 7,500,000 registered shares, payable in full, each with a nominal value of CHF 0.02, in connection with the exercise of option rights and/or shares granted to any employee of the Company or a subsidiary, and any consultant, Members of the Board of Directors, or other person providing services to the Company or a subsidiary.
2. Shareholders' subscription rights shall be excluded with regard to these shares. These new registered shares may be issued at a price below the current market price. The Board of Directors shall specify the precise conditions of issue including the issue price of the shares.
3. The exercise of conversion or option rights, as well as the waiver of such rights, may be exercised by written declaration or by electronic means.
4. The acquisition of registered shares in connection with employee participation and any further transfers of registered shares shall be subject to the restrictions specified in Article 4 of the Articles of Association.